One year outcomes of intravitreal faricimab for treatment Naïve neovascular AMD and associations with baseline aqueous humor cytokines

Satoru Inoda, Hidenori Takahashi, Yuto Hashimoto, Hana Yoshida, Hironori Takahashi, Takuya Takayama, Shouma Tsuchiya, Daizo Matsumoto, Hidetoshi Kawashima, Toshikatsu Kaburaki, Yasuo Yanagi · 2025

Read One year outcomes of intravitreal faricimab for treatment Naïve neovascular AMD and associations with baseline aqueous humor cytokines by Satoru Inoda, Hidenori Takahashi, Yuto Hashimoto, Hana Yoshida, Hironori Takahashi, Takuya Takayama, Shouma Tsuchiya, Daizo Matsumoto, Hidetoshi Kawashima, Toshikatsu Kaburaki, Yasuo Yanagi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12750000.txt.

Description

Satoru Inoda and co-authors report one-year results for a newer eye drug in age-related macular degeneration in this 2025 study. The wet form of the disease grows leaky vessels under the retina. The drug, faricimab, is injected into the eye to calm them. All patients were new to treatment when they started. A university clinic tracked thirty-four eyes of thirty-two patients for a year. Vision, retina thickness, and deeper layer thickness all improved.

Eye fluid taken at the start was tested for signaling proteins. One protein stood out in eyes that dried early, by week sixteen. Such markers might one day guide how often injections are needed. The study is real-world care, not a controlled trial. Its size is modest, and the authors report it as such. The paper adds to early evidence on this drug.

Catalog record

CREATORSatoru Inoda, Hidenori Takahashi, Yuto Hashimoto, Hana Yoshida, Hironori Takahashi, Takuya Takayama, Shouma Tsuchiya, Daizo Matsumoto, Hidetoshi Kawashima, Toshikatsu Kaburaki, Yasuo Yanagi
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12750000

Browse the full library · About the Tower of Babel